pharma& Receives EMA approval for Pegasys manufacturing site variation
pharma& has announced that the European Medicines Agency (EMA) has granted a variation to the Marketing Authorisation for Pegasys (peginterferon alfa-2a), allowing Loba biotech, a wholly owned manufacturing subsidiary of pharma&, to be included as an approved site for the production of the active pharmaceutical ingredient (API), peginterferon alfa-2a. The approval enables pharma& to begin Pegasys product
READ MORE